Major depression is a common mental disorder characterized by at least two weeks of depressed mood or loss of interest, often with sleep, appetite, energy, concentration, or self-worth changes. It can cause substantial functional impairment in daily life.
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07593222 |
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07562191 |
Inhaled DMT for Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE2 |
| NCT07560878 |
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression |
RECRUITING | EARLY_PHASE1 |
| NCT07503002 |
Shortened LSD Intervention for Major Depressive Disorder |
NOT_YET_RECRUITING | PHASE1 |
| NCT07479550 |
Study of Psilocybin Under Anesthesia Controlled by EEG |
NOT_YET_RECRUITING | PHASE2 |
| NCT07463911 |
Treatment Response In ECT Patients |
ACTIVE_NOT_RECRUITING | |
| NCT07380451 |
Modular Intervention for Depression Study |
RECRUITING | NA |
| NCT07226232 |
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression |
NOT_YET_RECRUITING | PHASE3 |
| NCT07226011 |
Accelerated High-Dose tDCS for Depression |
RECRUITING | NA |
| NCT07184697 |
Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD. |
ACTIVE_NOT_RECRUITING | NA |
